SCHEMBL967925

SCHEMBL967925

COc1ccc2c3c([nH]c2c1)CCN(CC(=O)N1CCN(C2CCC2)CC1)C3

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.53
KDM4E B2RXH2 2/20 0.53
HPGD P15428 1/20 0.53
BAZ2B Q9UIF8 1/20 0.47
KDR P35968 3/20 0.46
PARP1 P09874 2/20 0.45
ACHE P22303 1/20 0.45
KMT2A Q03164 2/20 0.45
TSHR P16473 1/20 0.45
NPC1 O15118 1/20 0.44
CASP1 P29466 2/20 0.43
CASP7 P55210 2/20 0.43
CFTR P13569 1/20 0.43
MEN1 O00255 1/20 0.42
ALOX15 P16050 1/20 0.42
MTNR1B P49286 2/20 0.42
ADRA1A P35348 1/20 0.42
ABCG2 Q9UNQ0 1/20 0.41
CNR1 P21554 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12947884 0.93 BAZ2B (0.56) ALDH1A1KDM4EHPGDBAZ2BKDR
SCHEMBL967938 0.86 HDAC1 (0.54) ALDH1A1KDM4EHPGDBAZ2BKDR
SCHEMBL970441 0.80 PARP1 (0.52) ALDH1A1KDM4EHPGDPARP1ADRA1A
SCHEMBL1017588 0.79 MTNR1B (0.52) ALDH1A1KMT2ATSHRMTNR1B
SCHEMBL970324 0.77 ALDH1A1 (0.64) ALDH1A1KDM4EHPGDPARP1KMT2A
SCHEMBL1014597 0.77 MTNR1B (0.53) ALDH1A1KMT2ATSHRMTNR1B
SCHEMBL967952 0.77 ALDH1A1 (0.45) ALDH1A1KMT2ATSHRMTNR1BCNR1
SCHEMBL969089 0.76 PARP1 (0.65) ALDH1A1KDM4EHPGDPARP1KMT2A
SCHEMBL967354 0.76 PARP1 (0.47) ALDH1A1KDM4EPARP1ACHEKMT2A
SCHEMBL968877 0.76 PARP1 (0.47) ALDH1A1KDM4EHPGDPARP1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2011-01-06 US claimed
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2011-01-06 US disclosed
EP-2162451-A2 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES Neurogen Corporation (US) 2010-03-17 EP disclosed
WO-2009003003-A2 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2008-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES HRH3, HRH4, HRH1 ALDH1A1 812/4885KDM4E 3037/4885HPGD 606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.